Sickle cell transplant study halted after just one patient
NCT ID NCT06078696
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called siplizumab alongside a stem cell transplant for people with severe sickle cell disease. The goal was to see if it could prevent the body from rejecting the new cells and reduce a serious side effect called graft-versus-host disease. Only one person enrolled before the study was stopped early, so we don't have enough information to know if it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA, SICKLE CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a computer program tame sickle cell pain crises?
- New App-Based program aims to help teens with sickle cell disease stay out of the ER
- Can telemedicine help kids with sickle cell disease get better care?
- New transplant approach offers hope for sickle cell patients without a perfect donor match
- Sickle cell hope: drug combo raises hemoglobin in early trial
- Could carbon monoxide be a medicine? new trial for sickle cell